05231nam 2200637 450 991046013530332120200520144314.01-118-88994-0(CKB)3710000000365738(EBL)1895710(SSID)ssj0001437628(PQKBManifestationID)12630170(PQKBTitleCode)TC0001437628(PQKBWorkID)11372766(PQKB)10927176(MiAaPQ)EBC1895710(DLC) 2015000334(Au-PeEL)EBL1895710(CaPaEBR)ebr11026086(CaONFJC)MIL770050(OCoLC)899267729(EXLCZ)99371000000036573820150310h20152015 uy 0engur|n|---|||||txtccrCardiovascular diseases from molecular pharmacology to evidence-based therapeutics /Y. Robert LiHoboken, New Jersey :John Wiley & Sons Inc.,2015.©20151 online resource (504 p.)Includes index.0-470-91537-4 Includes bibliographical references and index.Title Page; Copyright Page; Contents; Preface; List of Abbreviations; Unit I General Introduction; Chapter 1 Introduction to Cardiovascular Diseases; 1.1 Overview; 1.2 Definition of Cardiovascular Diseases; 1.3 Classification of Cardiovascular Diseases; 1.3.1 Classification Based on Anatomical Location; 1.3.2 Classification Based on the Involvement of Atherosclerosis; 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification; 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases; 1.4.1 NCDs and Cardiovascular Diseases: The Global Status1.4.2 The Status of Cardiovascular Diseases in the United States1.4.3 The Status of Cardiovascular Diseases in China; 1.5 Risk Factors of Cardiovascular Diseases; 1.5.1 Classification of Cardiovascular Disease Risk Factors; 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact; 1.6 Prevention and Control of Cardiovascular Diseases; 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level; 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health1.6.4 US DHSS "Million Hearts" Initiative; 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments; 1.7.1 Cardiovascular Risk Prediction; 1.7.2 Evidence-Based Treatments; 1.8 Summary of Chapter Key Points; 1.9 Self-Assessment Questions; References; Chapter 2 Introduction to Principles of Pharmacology; 2.1 Overview; 2.2 Definitions and History; 2.2.1 What Is Pharmacology?; 2.2.2 Definitions of Related Terms; 2.2.3 A Brief History of Pharmacology2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology2.3.1 Drug Names, Sources, Preparations, and Administration; 2.3.2 Pharmacokinetics; 2.3.3 Pharmacodynamics; 2.3.4 Drug Toxicity; 2.3.5 Pharmacogenetics and Pharmacogenomics; 2.4 Principles of Drug Discovery, Development, and Regulation; 2.4.1 Definitions; 2.4.2 The Paradigm of Drug Creation and Survival; 2.4.3 The FDA Drug Review and Approval Process; 2.5 Pharmacology Subspecialties; 2.6 Introduction to Cardiovascular Pharmacology; 2.6.1 Definition and Scope; 2.6.2 New Developments and Challenges2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases2.6.4 Polypill for the Management of Cardiovascular Diseases; 2.6.5 Protein Therapeutics of Cardiovascular Diseases; 2.6.6 Gene Therapy of Cardiovascular Diseases; 2.6.7 Stem Cell Therapy of Cardiovascular Diseases; 2.7 Summary of Chapter Key Points; 2.8 Self-Assessment Questions; References; Unit II Dyslipidemias; Chapter 3 Overview of Dyslipidemias and Drug Therapy; 3.1 Introduction; 3.2 Lipoprotein Metabolism; 3.2.1 Definition, Structure, and Classification of Lipoproteins3.2.2 Metabolic Pathways of Lipoproteins and Drug TherapyWritten in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology Includes guidelines and algorithms for pharmacCardiovascular systemDiseasesChemotherapyCardiovascular systemDiseasesDiagnosisElectronic books.Cardiovascular systemDiseasesChemotherapy.Cardiovascular systemDiseasesDiagnosis.616.1/061Li Robert Y.866523MiAaPQMiAaPQMiAaPQBOOK9910460135303321Cardiovascular diseases1934012UNINA01370nam 2200397Ka 450 991069689530332120080721154953.0(CKB)5470000002381924(OCoLC)234316277(EXLCZ)99547000000238192420080721d2008 ua 0engtxtrdacontentcrdamediacrrdacarrierFood stamps and obesity[electronic resource] what do we know ?Michele Ver Ploeg and Katherine Ralston[Washington, D.C.] :U.S. Dept. of Agriculture, Economic Research Service,[2008]iv, 31 pages digital, PDF fileEconomic information bulletin ;no. 34Title from title screen (viewed on July 21, 2008)."March 2008."Includes bibliographical references (pages 27-31).Food stamps and obesity Food stampsUnited StatesObesityUnited StatesFood stampsObesityVer Ploeg Michele1085439Ralston Katherine1398041United States.Department of Agriculture.Economic Research Service.GPOGPOBOOK9910696895303321Food stamps and obesity3482995UNINA01685nas 2200481-a 450 99620929970331620230506213019.0(OCoLC)762004837(CKB)2900000000000294(CONSER)--2012267029(MiAaPQ)616637(DE-599)ZDB2578690-8(EXLCZ)99290000000000029420110210a20099999 --- -porur|n|||||||||txtrdacontentcrdamediacrrdacarrierRevista ibero-americana de estratégia[São Paulo] Universidade Nove de JulhoRefereed/Peer-reviewed2176-0756 "Mission: To serve as a vehicle for dissemination of theoretical and applied research in the strategy area broadly defined to include that study of strategy across organizations, nations, markets, and in society in general."--English Focus and scope page.RIAEIbero American strategy journalRevista de estratégia ibero-americanaRev. Ibero-Am. Estratég.Strategic planningPeriodicalsManagementPeriodicalsManagementfast(OCoLC)fst01007141Strategic planningfast(OCoLC)fst01134371Periodicals.fastStrategyStrategic planningManagementManagement.Strategic planning.Universidade Nove de Julho.JOURNAL996209299703316Revista ibero-americana de estratégia2124678UNISA02581 am 2200589 n 450 991056779760332120240104030717.0979-1-03-000767-110.4000/books.pub.47479(CKB)4100000012875264(FrMaCLE)OB-pub-47479(PPN)26327120X(EXLCZ)99410000001287526420220513j|||||||| ||| 0freuu||||||m||||Description systématique du mboLangue bantoue A.15Christiane Félicité ÉwanéPessacPresses Universitaires de Bordeaux20211 online resource (332 p.) 979-1-03-000076-4 Voici un livre qui vient à son heure. C’est un heureux événement pour la langue mbo et pour la linguistique africaine. Grâce à la somme des données dégagées par la description, il ouvre, pour la langue mbo, des perspectives prometteuses en termes d’aménagement orthographique, terminologique et grammatical, ce qui ne manquera pas de faciliter son emploi dans tous les domaines de la vie moderne au bénéfice de ses usagers : alphabétisation, scolarisation, création littéraire, communication dans la presse, à la radio et à la télévision. Ce livre sera utile aux chercheurs car il constitue une contribution importante à la connaissance des langues bantoues de la zone A considérée par les spécialistes comme l’une des plus complexes et des moins explorées de l’ensemble du domaine. Enfin il s’adresse à la fois à ceux qui parlent le mbo et à ceux qui voudraient l’étudier ou l’enseigner.Linguisticsdescription linguistiquesyntaxephonologiesynchronielangue bantoueethnonymeglossonymelangue à classesstructure syllabiquetonologiemorphologieLinguisticsdescription linguistiquesyntaxephonologiesynchronielangue bantoueethnonymeglossonymelangue à classesstructure syllabiquetonologiemorphologieÉwané Christiane Félicité1458386Musanji Ngalasso-Mwatha1458387FR-FrMaCLEBOOK9910567797603321Description systématique du mbo3658267UNINA02919oam 2200577I 450 991082301900332120240314024459.00-429-16843-81-4665-8714-810.1201/b15301 (CKB)2670000000394615(EBL)1335842(OCoLC)855504706(SSID)ssj0000876664(PQKBManifestationID)11535867(PQKBTitleCode)TC0000876664(PQKBWorkID)10923356(PQKB)10353397(OCoLC)857081231(MiAaPQ)EBC1335842(OCoLC)853508638(EXLCZ)99267000000039461520180331d2014 uy 0engur|n|---|||||txtccrBiomarkers in cardiovascular diseases /editors, Dimitris Tousoulis, Christodoulos Stefanadis1st ed.Boca Raton :CRC Press,2014.1 online resource (450 p.)Description based upon print version of record.1-4665-8715-6 Includes bibliographical references and index.pt. 1. Classical biomarkers -- pt. 2. Novel biomarkers.The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book--Provided by publisher.Cardiovascular systemDiseasesDiagnosisCardiovascular systemDiseasesPreventionCardiovascular systemDiseasesDiagnosis.Cardiovascular systemDiseasesPrevention.616.1075Tousoulis Dimitris897327Stefanadis Christodoulos1600452MiAaPQMiAaPQMiAaPQBOOK9910823019003321Biomarkers in cardiovascular diseases3923551UNINA05591oam 22010934 450 991082644360332120240402023454.01-4623-7092-61-4518-7104-X97866128419721-4527-9649-11-282-84197-1(CKB)3170000000055141(EBL)1586706(SSID)ssj0000944133(PQKBManifestationID)11518474(PQKBTitleCode)TC0000944133(PQKBWorkID)10983294(PQKB)11410749(OCoLC)762062544(IMF)WPIEE2008246(MiAaPQ)EBC1586706(EXLCZ)99317000000005514120020129d2008 uf 0engur|n|---|||||txtccrGlobalization Drives Strategic Product Switching /Marialuz Moreno Badia, Veerle Slootmaekers, Ilke Van Beveren1st ed.Washington, D.C. :International Monetary Fund,2008.1 online resource (68 p.)IMF Working PapersIMF working paper ;WP/08/246Description based upon print version of record.1-4519-1557-8 Includes bibliographical references.Cover Page; Title Page; Copyright Page; Contents; I. Introduction; II. Industry Dynamics in Estonia; 1. Exits and Industry Switches, 1997-2004; 2. Sector Distribution; 3. Four-Digit Product Switches Decomposed25; 4. Destination of Product Switches by Technology Class; III. Determinants of Firm Dynamics; 5. Summary Statistics; A. Firm Characteristics; B. Product Market Characteristics: Domestic Market; C. Product Market Characteristics: International Competition; IV. Results; A. Baseline Results; 6. Baseline Specification; B. Self-Selection into New Markets7. Product Switching Versus Industry Switching8. Industry Switching: Manufacturing versus Services; 9. Unit Value Difference Between Industry of Origin and Destination; V. Robustness Checks; A. Results by Size Class; 1. Sample Size Distribution; 10. Determinants of Firm Dynamics Across Size Categories; B. Results by Time Period; 11. Determinants of Firm Dynamics Across Time; VI. Conclusions; Appendix I. Data and Sample Selection; Appendix II. Definitions of Variables; Appendix III. Sector Classification According to Technology Intensity and Knowledge; References; FootnotesUsing firm-level data for Estonia for the years 1997-2005, we analyze the impact of international competition on firm dynamics, considering both firm closedown and product switching. We contribute to the literature in two important ways: (1) this is the first paper to study the determinants of exit and product switching in an emerging market; and (2) we consider explicitly the role of export opportunities. Our results indicate that globalization does not affect firm exit significantly but it is an important factor explaining product switching. Previous studies on industrial countries have shown that product switching has been a defensive strategy against low-cost imports. In contrast, our results suggest that Estonian firms have switched products as an offensive strategy to take advantage of the export opportunities created by trade liberalization.IMF Working Papers; Working Paper ;No. 2008/246GlobalizationEconomic aspectsEstoniaEconometric modelsProduct managementEstoniaEconometric modelsCosts, IndustrialEstoniaEconometric modelsExports and ImportsimfFinance: GeneralimfIndustries: ManufacturingimfTrade: GeneralimfGeneral Financial Markets: General (includes Measurement and Data)imfIndustry Studies: Manufacturing: GeneralimfInternational economicsimfFinanceimfManufacturing industriesimfExportsimfCommodity marketsimfCompetitionimfManufacturingimfImportsimfInternational tradeimfFinancial marketsimfEconomic sectorsimfCommodity exchangesimfEstonia, Republic ofimfGlobalizationEconomic aspectsEconometric models.Product managementEconometric models.Costs, IndustrialEconometric models.Exports and ImportsFinance: GeneralIndustries: ManufacturingTrade: GeneralGeneral Financial Markets: General (includes Measurement and Data)Industry Studies: Manufacturing: GeneralInternational economicsFinanceManufacturing industriesExportsCommodity marketsCompetitionManufacturingImportsInternational tradeFinancial marketsEconomic sectorsCommodity exchanges337Moreno Badia Marialuz1123353Slootmaekers Veerle1643720Beveren Ilke Van1700325DcWaIMFBOOK9910826443603321Globalization Drives Strategic Product Switching4083251UNINA